A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 1203-1207

  Renouf, Daniel J ^a   Tang, Patricia A ^b   Major, Pierre ^c   Krzyzanowska, Monika K ^a   Dhesy Thind, Bindi ^c   Goffin, John R ^c   Hedley, David ^a   Wang, Lisa ^a   Doyle, L ^d   Moore, Malcolm J ^a,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d CTEP   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Eribulin mesylate; Halichodrin B; Pancreatic cancer; Phase II

Indexed keywords

ERIBULIN; GEMCITABINE;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; THROMBOSIS; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; ETHERS, CYCLIC; FEMALE; FURANS; HUMANS; KETONES; MACROLIDES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TUBULIN MODULATORS;

EID: 84862255849     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9673-x     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96 (Pubitemid 351521864)
2. Glimelius B, Hoffman K, Sjoden PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593-600 (Pubitemid 26285639)
3. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
4. Van Cutsem E, Vervenne WL, Bennouna J et al (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237
5. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
6. Pelzer U, Kubica K, Stieler J, et al (2008). A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26Abstr 4508
7. Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787-4792 (Pubitemid 350086482)
8. Tang P. Gill S, Au HJ et al (2009) Phase II trial of erlotinib in advanced pancreatic cancer. J Clin Oncol 27
9. Renouf D, Moore M (2010) Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther 10:529-540
10. Cantore M, Rabbi C, Fiorentini G et al (2004) Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 67:93-97 (Pubitemid 39482675)
11. Demols A, Peeters M, Polus M et al (2006) Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancre-atic adenocarcinoma: a phase II study. Br J Cancer 94:481-485 (Pubitemid 43289750)
12. Xiong HQ, Varadhachary GR Blais JC et al (2008) Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113:2046-2052
13. Sudo K, Yamaguchi T, Nakamura K et al (2011) Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 67:249-254
14. Wolpin BM, Hezel AF, Abrams T et al (2009) Oral mtor inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27:193-198
15. Katopodis O, Polyzos A, Kentepozidis N et al (2011) Second-line chemotherapy with capecitabine (xeloda) and docetaxel (taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol 67:361-368
16. O'Reilly EM, Niedzwiecki D, Hall M et al (2010) A cancer and leukemia group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 15:1310-1319
17. Tempero MA, Arnoletti JP, Behrman S et al (2010) Pancreatic adenocarcinoma. J Natl Compr Canc Netw 8:972-1017
18. Jordan MA, Kamath K, Manna T et al (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086-1095 (Pubitemid 41079102)
19. Kuznetsov G, Towle MJ, Cheng H et al (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64:5760-5766 (Pubitemid 39095575)
20. Okouneva T, Azarenko O, Wilson L et al (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic meta-phase. Mol Cancer Ther 7:2003-2011
21. Towle MJ, Salvato KA, Budrow J et al (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013-1021 (Pubitemid 32174419)
22. Bekaii-Saab TS, Villalona-Calero MA (2005) Preclinical experience with docetaxel in gastrointestinal cancers. Semin Oncol 32:S3-S9 (Pubitemid 40726039)
23. Saif MW, Syrigos K, Penney R et al (2010) Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospec-tive study. Anticancer Res 30:2905-2909
24. Turrini O, Ychou M, Moureau-Zabotto L et al (2010) Neo-adjuvant docetaxel-based chemoradiation for resectable adenocar-cinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol 36:987-992
25. Kuznetsov G, TenDyke K, Yu MJ et al (2007) Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Proc Am Assoc Cancer Res 48:275
26. Konig J, Hartel M, Nies AT et al (2005) Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 115:359-367 (Pubitemid 40663738)
27. Akada M, Crnogorac-Jurcevic T, Lattimore S et al (2005) Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 11:3094-3101 (Pubitemid 40525216)
28. Vahdat LT, Pruitt B, Fabian CJ et al (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954-2961
29. Cortes J, Vahdat L, Blum JL et al (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28:3922-3928
30. Cortes J, O'Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914-923
31. Goel S, Mita AC, Mita M et al (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtu-bule dynamics, in patients with advanced solid malignancies. Clin CancerRes 15:4207-4212
32. Tan AR, Rubin EH, Walton DC et al (2009) Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 15:4213-4219
33. Arnold SM, Moon J, Williamson SK, et al (2009) Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest oncology group trial S0618. Invest New Drugs
34. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1-10 (Pubitemid 19099520)
35. Zee B, Melnychuk D, Dancey J et al (1999) Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Stat 9:351-363 (Pubitemid 29262953)
36. Dent S, Zee B, Dancey J et al (2001) Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol 19:785-791 (Pubitemid 32119094)